180 related articles for article (PubMed ID: 33741738)
21. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
22. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
24. Subtle structural changes in tetrahydroquinolines, a new class of nonsteroidal selective androgen receptor modulators, induce different functions.
Nagata N; Kawai K; Nakanishi I
J Chem Inf Model; 2012 Aug; 52(8):2257-64. PubMed ID: 22794275
[TBL] [Abstract][Full Text] [Related]
25. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
[TBL] [Abstract][Full Text] [Related]
26. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.
Sundén H; Holland MC; Poutiainen PK; Jääskeläinen T; Pulkkinen JT; Palvimo JJ; Olsson R
J Med Chem; 2015 Feb; 58(3):1569-74. PubMed ID: 25646649
[TBL] [Abstract][Full Text] [Related]
28. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
29. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
30. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
[TBL] [Abstract][Full Text] [Related]
31. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist.
Cole RN; Chen W; Pascal LE; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2022 Apr; 21(4):483-492. PubMed ID: 35058329
[TBL] [Abstract][Full Text] [Related]
32. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
[TBL] [Abstract][Full Text] [Related]
33. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
[TBL] [Abstract][Full Text] [Related]
34. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
35. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
36. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA
J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014
[TBL] [Abstract][Full Text] [Related]
37. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
38. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
[TBL] [Abstract][Full Text] [Related]
39. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
